Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 38 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

811 AR166, a novel tri-specific immunocytokine, overcomes anti-PD-1 resistance by delivering cis-acting IL-2v via dual PD-1 and LAG-3 targeting

  • Su-Hyung Park1
  • Wooick Jang2
  • Jinkeol Mok2
  • Juhan Yoon3
  • Jaehyeon Kim4
  • Jaeho Song5
  • Jae-Seok Lee5
  • Saehyung Lee6
  • Seon-Mi Yu5
  • Jihye Yoon5
  • Wanki Park3
  • Jung Ho Yoon5
6 more authors
  • Young Woo Park3
  • Seo-Young Koo5
  • Min-Young Park5
  • Seoyun Yang5
  • Hye Kyung Hong7
  • Yong Beom Cho7
7 affiliations
  1. 1Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea (the Republic of)
  2. 22Y-Biologics Inc., Daejeon, Republic of Korea
  3. 3Y-Biologics, Inc., Daejeon, Republic of Korea
  4. 45Medpacto, Inc., Seoul, Korea, Republic of Korea
  5. 5Y-Biologics Inc., Daejeon, Republic of Korea
  6. 63ABION Inc., Seoul, Gwanak-gu, Republic of Korea
  7. 7Samsung Medical Center, Seoul, Republic of Korea
Open at sourcePDFDOICite

Related

  1. CBX3 Deletion Overcomes Ferroptosis Resistance in Colorectal Cancer by Targeting IFNγ/SLC7A11/SLC3A2 Axis
    Y. Xiang, Y. Fu, C. Desterke +13
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  2. Targeting SLC1A5-mediated glutamine metabolism overcomes PARP inhibitor resistance in ovarian cancer.
    Fang Han, Hongjie Du, Kunlin Tian +4
    Cell death & diseasePeer-reviewedCC BYFull textOncologyEurope PMCDOAJ
  3. Fingolimod overcomes cisplatin resistance in esophageal squamous cell carcinoma by targeting NUP54 to disrupt homologous recombination repair.
    Duo Cao, Jin Liu, Guoliang Chen +11
    Cell communication and signaling : CCSPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCPMC
  4. Targeting oxidative phosphorylation with lixumistat overcomes PARP inhibitor resistance in ovarian cancer
    Sa Deok Hong, Nar Bahadur Katuwal, Mithun Ghosh +5
    Cell Death & DiseasePeer-reviewedCC BY 4.0Full textOncologyPMC
  5. Fc-Dependent Targeting of the GAS6-MERTK Axis With Monoclonal and Bispecific Antibodies Overcomes Drug Resistance Across EGFR Mutations in Exons 19, 20, and 21.
    Suvendu Giri, Boobash Raj Selvadurai, Nitin Gupta +26
    Advanced science (Weinheim, Baden-Wurttemberg, Germany)Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{park2026ar166,
  title = {{811 AR166, a novel tri-specific immunocytokine, overcomes anti-PD-1 resistance by delivering cis-acting IL-2v via dual PD-1 and LAG-3 targeting}},
  author = {Su-Hyung Park and Wooick Jang and Jinkeol Mok and Juhan Yoon and Jaehyeon Kim and Jaeho Song and Jae-Seok Lee and Saehyung Lee and Seon-Mi Yu and Jihye Yoon and Wanki Park and Jung Ho Yoon and Young Woo Park and Seo-Young Koo and Min-Young Park and Seoyun Yang and Hye Kyung Hong and Yong Beom Cho},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0811},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0811},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 811 AR166, a novel tri-specific immunocytokine, overcomes anti-PD-1 resistance by delivering cis-acting IL-2v via dual PD-1 and LAG-3 targeting
AU  - Su-Hyung Park
AU  - Wooick Jang
AU  - Jinkeol Mok
AU  - Juhan Yoon
AU  - Jaehyeon Kim
AU  - Jaeho Song
AU  - Jae-Seok Lee
AU  - Saehyung Lee
AU  - Seon-Mi Yu
AU  - Jihye Yoon
AU  - Wanki Park
AU  - Jung Ho Yoon
AU  - Young Woo Park
AU  - Seo-Young Koo
AU  - Min-Young Park
AU  - Seoyun Yang
AU  - Hye Kyung Hong
AU  - Yong Beom Cho
PY  - 2026
DA  - 2026/11/07
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0811
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0811
SN  - 2051-1426
ER  -